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Methods
We searched seven electronic databases (Cinahl, Cochrane Controlled Trials Register, DARE, Embase, Medline, PsycINFO and SIGLE) without language restrictions from January 1990 to October 2007 and reference lists of retrieved articles to identify studies published before 1990. We included studies examining primary outcomes (pelvic inflammatory disease, ectopic pregnancy, infertility, adverse pregnancy outcomes, neonatal infection, chlamydia prevalence) and harms of chlamydia screening in men and non-pregnant and pregnant women. We extracted data in duplicate and synthesized the data narratively or used random effects meta-analysis, where appropriate.
Results
We included six systematic reviews, five randomized trials, one nonrandomized comparative study and one time trend study. Five reviews recommended screening of women at high risk of chlamydia. Two randomized trials found that register-based screening of women at high risk of chlamydia and of female and male high school students reduced the incidence of pelvic inflammatory disease in women at 1 year. Methodological inadequacies could have overestimated the observed benefits. One randomized trial showed that opportunistic screening in women undergoing surgical termination of pregnancy reduced post-abortal rates of pelvic inflammatory disease compared with no screening. We found no randomized trials showing a benefit of opportunistic screening in other populations, no trial examining the effects of more than one screening round and no trials examining the harms of chlamydia screening.
Conclusion
There is an absence of evidence supporting opportunistic chlamydia screening in the general population younger than 25 years, the most commonly recommended approach. Equipoise remains, so highquality randomized trials of multiple rounds of screening with biological outcome measures are still needed to determine the balance of benefits and harms of chlamydia screening.
Introduction
Chlamydia screening is widely promoted in highincome countries as an intervention to prevent reproductive tract morbidity, including infertility, in women by reducing chlamydia transmission. [1] [2] [3] A National Chlamydia Screening Programme in England 1 and regional Infertility Prevention Programs in the United States 4 offer chlamydia screening to eligible, sexually active individuals younger than 25 years when they attend consultations at specified health care, or other, settings. This approach is known as opportunistic screening (Box 1). The other main approach is registerbased screening (Box 1, also known as call-recall, proactive or population based). Key features of registerbased screening are an up-to-date register of those eligible for screening, which can be used to send proactive invitations for screening; identifying those who have not responded to an invitation and sending reminders; sending repeat invitations at regular defined intervals; compiling regular reports of the coverage; and follow-up of testing. 5 Register-based chlamydia screening is being piloted in three regions of the Netherlands from 2008. 6 The way in which screening services are organized and delivered can affect their success. Regular screening and follow-up are needed to realize sustainable population benefits. 7 This might be particularly important for communicable diseases where asymptomatic and repeated infections are common. 8 These requirements are difficult to achieve and monitor with opportunistic approaches, which require the target group to use health services regularly, practitioners to offer repeat tests at appropriate intervals and administrative systems to track individuals attending multiple screening venues. Opportunistic cervical cancer screening, offered in the 1960s and 1970s by general practitioners and family planning clinics in the United Kingdom, was ineffective. 9 Older women at highest risk were screened infrequently or not at all, whilst those at low risk were screened repeatedly. The fall in the death rate from cervical cancer, which began before screening was introduced, did not accelerate until an organized call-recall system, which increased regular coverage to 80%, was introduced in 1988. 10 The primary objective of a screening programme is to reduce mortality or morbidity. 5, 9 The strength of evidence supporting chlamydia screening as a population-level intervention has, however, been challenged. 11, 12, 13, 14 The objective of this study was to examine the research evidence about the effectiveness of screening to prevent chlamydia-associated morbidity and transmission systematically, with a focus on the organizational approach.
Methods

Data sources and searches
We searched Cinahl, Cochrane Controlled Trials Register, Database of Abstracts of Research Effectiveness, Embase, Medline, PsycINFO and SIGLE from January 1990 to October 2007. We searched the reference lists of included articles to identify additional relevant articles, including those published before 1990. We had no language restrictions. We used subject heading and free text terms that combined Chlamydia trachomatis infections or pelvic inflammatory disease with terms for screening (Supplementary Information 1).
Box 1 Definitions used
Screening
Members of a defined population, who may not know they are at risk of a disease or its complications, are asked a question or offered a test to identify those who are more likely to be helped than harmed by further tests or treatment. 49 Screening programme A continuing public health service that ensures screening is delivered at sufficiently regular intervals to a high enough proportion of the target population to achieve defined levels of benefit at the population level, while minimizing harm. 12 Register-based screening Registers are used to identify and enumerate the target population (e.g. in a geographical area, practice list of a general practitioner or members of a health maintenance organization), to send invitations for screening, to send reminders to those who have not attended and to send regular repeat invitations at appropriate intervals. Invitations are sent to individuals irrespective of their record of health service use. Also known as population, proactive, call-recall, cyclical, active or systematic screening. 49 Opportunistic screening A health professional offers a screening test to patients attending health care or other defined settings for any reason. Individuals who do not use relevant health services will not have an opportunity to be offered screening. The health professional takes responsibility for repeating the test offer at appropriate intervals. 49 
Study selection
We included studies reporting primary biological outcomes of any approach to chlamydia screening in adult women and men, and harms resulting from screening. The following were considered as primary outcomes: chlamydia incidence or prevalence; pelvic inflammatory disease, ectopic pregnancy and infertility; adverse pregnancy outcomes; neonatal morbidity or mortality; and male infertility. Psychological distress, partner violence and relationship breakdown were considered as harms. We included systematic reviews, randomized controlled trials, non-randomized comparative studies and observational time trend studies if they included data from at least two time points before the introduction of the intervention. 15 Two reviewers screened titles and abstracts to identify potentially relevant articles. Full-text articles were then read independently. Discrepancies were resolved by discussion to reach consensus about the list of articles to include.
Data extraction and quality assessment
We used published definitions of opportunistic and register-based screening to determine the approach used in included studies (Box 1). Two independent reviewers assigned the screening approach and extracted data. Discrepancies were resolved by discussion, or by consultation with a third reviewer. We used criteria published by the United Kingdom National Institute for Health and Clinical Excellence for each study design to assess the quality of reporting of the study methods. 15 Supplementary Tables 1a-d shows the details of the quality assessments and criteria.
Data synthesis and analysis
We used narrative methods to describe the evidence. If two or more trials examined the same intervention and outcome, we combined the results statistically in a meta-analysis using a random effects model. We examined statistical evidence of heterogeneity due to between-trial variation using the I 2 statistic. 16 A detailed report of this study has been published. 13 
Results
Our literature searches identified 2323 unique references ( Figure 1 Table 2 , References s1-s36). 13 Seventeen of these were time trend studies that did not report data from the time period before the introduction of the screening intervention (s20-s36). Eight were controlled trials for which the outcome was screening uptake (s6, 7, 11, 13, [15] [16] [17] 19) and that have been summarized elsewhere. 13 We excluded two literature reviews that informed recommendations about screening in the United Kingdom (s1) and updated recommendations in Canada (s2) because there was no description, or reference to a description, that could determine whether or not they were systematic reviews. We included six systematic reviews, [17] [18] [19] [20] [21] [22] five randomized trials, [23] [24] [25] [26] [27] one non-randomized comparative study 28 and one time trend study. 29 We found no randomized controlled trials of the effects of opportunistic chlamydia screening in nonpregnant women, pregnant women in antenatal clinics or men. We found no randomized trial reporting the outcomes of infertility in women or men, ectopic pregnancy, adverse pregnancy outcomes, neonatal morbidity or mortality and no trials that examined the effects of more than one round of any screening intervention. We found no trials reporting harms of chlamydia screening.
Systematic reviews
Four systematic reviews [17] [18] [19] [20] directly informed published national guidelines on chlamydia screening in Canada, 17 Scotland, 18 and the United States 2 ( Table 1 ). The most recent review, by the United States Preventive Services Task Force, 20 updated an earlier full review. 19 Four reviews were based on searches of multiple electronic databases. 18, 19, 21, 22 Our literature searches identified all studies cited by the reviews as evidence of effectiveness. No review separated studies according to the organizational approach to screening. Among five reviews that assessed the same trial of a register-based approach, 23 two graded this as good evidence 19, 22 and one as fair evidence 17 to recommend screening of women at high risk of chlamydia. The Scottish guideline recommended opportunistic testing of women at high risk of chlamydia but noted that no randomized trial supported this. 18 This guideline is being updated.
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One review graded the same study as a low-quality randomized trial with no recommendation. 21 Three reviews recommended chlamydia screening before termination of pregnancy. 18, 21, 22 Three reviews cited evidence from ecological time trend studies as supportive evidence in favour of chlamydia screening programmes. 19, 21, 22 Register-based screening We found three randomized controlled trials [23] [24] [25] and one non-randomized comparative study 28 reporting the effects of register-based chlamydia screening on the incidence of pelvic inflammatory disease or on chlamydia prevalence (Tables 2 and 3 ).
Effects on reproductive tract morbidity in women Two randomized controlled trials (3537 women enrolled) found that the risk of pelvic inflammatory disease in women invited to be screened was about half that of control groups 1 year after a single round of register-based screening [summary risk ratio 0.46, 95% confidence interval (CI) 0.27-0.78, I
2 ¼ 0%]. 23, 24 There were biases in the design of both studies (Tables 2 and 3, Supplementary Table 1a ). In the earliest published study, 23 the authors used the register of a health maintenance organization in the United States to identify, invite and follow-up their target population. Overall, 36 547 women were randomized first to screening and control groups, and consent for inclusion was sought if their responses to a postal questionnaire showed them to be single, non-pregnant and at high risk of chlamydia (score 43, based on age 424 ¼ 1, black race ¼ 2, nulligravid ¼ 1, douching in past 12 months ¼ 1 and 52 sexual partners in past 12 months ¼ 1). Women randomized to the screening group only were also telephoned to increase the number with a risk assessment and allow screening appointments to be made. These practices changed the planned ratio in intervention and control groups from 1:2 to 1:1.6 (total 2607). Sixty-four per cent of women in the intervention group and an unknown proportion in the control group were screened for chlamydia. Østergaard et al. 24 conducted a cluster randomized trial in 17 high schools in Aarhus County, Denmark (8909 students). Sexually active female and male students responding to the invitation were asked to collect urine and/or vaginal specimens at home, or told that they could be tested at a local health clinic. Response rates were higher in those assigned to the intervention (32% of those randomized) than control group (24%). Participants in the intervention group were given additional information about the importance of partner notification if diagnosed with chlamydia. 31 Ascertainment of pelvic inflammatory disease was unblinded, and loss to follow-up 1 year later was nearly 50% (Supplementary Table 1a ).
Effects on chlamydia transmission
Two randomized trials and one non-randomized comparative study reported effects of register-based screening on chlamydia prevalence, as a measure of chlamydia transmission (Tables 2 and 3) . 24, 25, 28 There were biases in all studies (Supplementary Table 1a) , and results could not be combined statistically because of differences in the ways the data were collected and reported. Østergaard et al. 24 found fewer diagnosed infections at follow-up in female students who had been proactively invited to provide home-collected vaginal specimens compared with controls who were told that they could visit their general practitioner (Tables 2 and 3 ). Cohen et al. 28 compared infection rates between three schools that had provided chlamydia screening over a 3-year-period with a Review questions are those specified by the authors. Only questions and included studies directly related to evidence for the effectiveness of screening are included here. Reviews also examined evidence for chlamydia prevalence, risk factors, accuracy of diagnostic tests and cost-effectiveness. CCT, controlled clinical trial; RCT, randomized controlled trial; f, female; m, male; wm, woman months; mth, months; PID, pelvic inflammatory disease.
non-randomly selected group of five schools with no screening. The infection rate in intervention compared with control schools was lower at follow-up in boys but not in girls (Tables 2 and 3) . In both studies, there was no baseline assessment or treatment in control groups, so, at follow-up, both incident and prevalent infections would be detected, whereas only incident infections would be detected in intervention schools. Hodgins et al. 25 invited all adults in six Inuit villages in Canada to provide urine specimens as part of an intensive sexual health education and promotion campaign. Chlamydia prevalence 1 year after screening in intervention villages fell (Tables 2 and 3 ). In six comparison villages where there was no campaign but opportunistic testing was available, prevalence 1 year later had not changed.
Opportunistic screening
Effects on reproductive tract morbidity in women We found two randomized trials (2263 women) investigating the effects of opportunistic chlamydia screening on pelvic inflammatory disease in women requesting surgical termination of pregnancy. 26, 27 In women in Sweden offered pre-operative chlamydia screening and treatment, the risk of post-abortal pelvic inflammatory disease was about half that in women in the control group who received diagnostic testing if they had post-operative symptoms (risk ratio 0.50, 0.27-0.95, Tables 2 and 3) . 26 Details of randomization, concealment and blinding of outcome assessment were not reported. The other study compared a strategy of pre-operative screening using an enzyme linked immunoassay followed by treatment of positive cases with universal perioperative antibiotic prophylaxis in Scotland. 27 The study was terminated before reaching the required sample size, but there was weak evidence of more episodes of post-operative pelvic inflammatory disease at 8 weeks with the screening strategy than with universal prophylaxis (risk ratio 1.47, 0.97-2.23, Tables 2 and 3 ). Re-infection was not assessed as an outcome, but partner management in women randomized to screening was poor: of 45 women with positive chlamydia or gonorrhoea tests, 4 partners were documented to have received treatment. 27 Effects on chlamydia transmission We included one ecological study that reported time trends in diagnosed chlamydia rates in Uppsala County, Sweden. 29 Herrmann and Egger used microbiology records and population data before and after chlamydia testing in health care settings became widespread. 29 In 1988, chlamydia became a notifiable infection, and partner notification was mandatory. Five youth clinics providing free chlamydia testing and treatment were established, and there was a publicity campaign. Chlamydia testing was also available in other health care settings, but the activities were not coordinated as a screening programme. Chlamydia rates per 1000 tests were reported by year for 3 years before opportunistic testing became widely available (1985-87) and 6 years after (1988-93). The chlamydia infection rate fell in both time periods in both women and men. An increase in male rates at the end of the study period was noted as an indication of increasing incidence.
Discussion
Our systematic review assessed evidence for the effectiveness of chlamydia screening in preventing chlamydia-associated morbidity or transmission of infection. Trial reporting quality was generally poor, and there were methodological weaknesses that could have biased the results of all included studies. In two randomized trials, a single round of register-based screening was associated with a reduced incidence of pelvic inflammatory disease in women at 1 year. Information about the effects of any chlamydia screening approach on transmission of infection was difficult to interpret. Trials of opportunistic chlamydia screening have only been conducted in women undergoing surgical termination of pregnancy. We found no evidence for the effectiveness of opportunistic screening in any other population, of multiple rounds of any screening approach or about the harms of chlamydia screening (Table 4) .
Strengths and weaknesses
The strengths of this review were that we conducted comprehensive literature searches of multiple databases without language restrictions, and used rigorous methods to identify, appraise and synthesize the evidence. It is, therefore, unlikely that we excluded any important studies during the dates covered by the search. The main weakness of the review was that it was not possible to combine effect estimates statistically for most comparisons because of the small numbers of studies, and differences in the interventions, populations or data reporting. Incomplete reporting of methods made it difficult to interpret the findings of many studies.
Comparison with other systematic reviews
The results of our systematic review differ from others, [17] [18] [19] [20] [21] [22] which concluded that there was fair or good evidence to recommend chlamydia screening. First, by stratifying results according to the organizational approach to chlamydia screening, we showed that any evidence of a beneficial effect applied only to register-based interventions, and this was limited by poor trial quality. Second, we found some evidence that chlamydia screening in men might contribute to a reduction in the incidence of pelvic inflammatory disease in women (Table 4 ). The cluster randomized trial by Østergaard and colleagues 31 involved both male and female students. If we presume that some students at least were in shared sexual networks, the reduction in pelvic inflammatory disease in women 24 could be attributed in part to screening and treatment of chlamydia-infected men. The United States Preventive Services Taskforce 20 reviewed the same trial but concluded that there were no studies showing that chlamydia screening in men produces benefits in women. New Canadian guidelines on sexually transmitted infections noted a gap in the evidence about chlamydia screening in men, citing the US review. 32 Third, we did not find the results of time trend studies to be consistent with randomized controlled trial results. 19, 21, 22 The only eligible study in our review showed that chlamydia rates were falling in Uppsala County, Sweden, before opportunistic testing became widespread. 29 Interpretation of the evidence It has been argued that further randomized trials of the primary outcomes of chlamydia screening are unnecessary. 33 Our review suggests that clinical equipoise remains because the quality of trials so far does not allow the benefits or harms of chlamydia screening to be quantified accurately enough. 11, 12, 14 Both trials of register-based screening must have overestimated the effect of screening: 23, 24 Chlamydia trachomatis is implicated in about 30% of acute pelvic inflammatory disease, 34 so even if screening and treatment could prevent all cases resulting from ascending chlamydia, a halving of the overall risk of pelvic inflammatory disease is implausible. Seven of nine cases of pelvic inflammatory disease in the trial by Scholes and colleagues 23 were in women tested for chlamydia, so the intervention did not prevent these cases. Furthermore, results from women at high risk of chlamydia in this trial might not be generalizable to all women younger than 25 years, and additional contacts with those invited for screening could have exaggerated uptake or changed behaviours, which might have increased differences in outcomes between groups. In the trial by Østergaard et al., 24 open outcome assessment could have increased the estimated effect if symptoms were more likely to be assigned to pelvic inflammatory disease in the unscreened group and to other causes in the screened group. Differential enrolment rates and high losses to follow-up might also have resulted in systematic differences between intervention and control groups. The large effects seen in trials have not been replicated in observational studies. Rates of hospitalization for pelvic inflammatory disease among 28 000 new recruits in the United States Army were similar in screened compared with unscreened women after 18 months (relative risk, adjusted for age, race, education and aptitude 0.94, 95% CI 0.69-1.29). 35 This slight reduction and the lower overall hospitalization (adjusted relative risk 0.94, 95% CI 0.90-0.99) among screened women could reflect an unmeasured 'healthy screenee' effect. 5 The ways in which the interventions examined could have prevented pelvic inflammatory disease have not been examined critically. A single screening test could only have a substantial direct effect if most infections detected were recently acquired and were treated before causing upper genital tract inflammation. This is unlikely because chlamydia persists asymptomatically for up to 5 years after diagnosis, 36 so most infections in a previously unscreened population would already have been present for some time and might already have caused tubal damage. Alternatively, high enough levels of screening uptake and partner notification would interrupt community transmission and reduce exposure. Once off screening uptake of 33% among school students in half the schools in one Danish community would probably not have reduced transmission substantially, 24 and health maintenance organization members are not a geographical community, so transmission is unlikely to have been affected. 23 Neither trial reported partner treatment rates. 23, 24 In one trial that examined pre-abortion screening, only 10% of male partners of women with either chlamydia or gonorrhoea were treated. 27 Mathematical models provide the only source of information about how chlamydia screening would prevent pelvic inflammatory disease in the long term. In these models, the reduction in pelvic inflammatory disease depends on reducing transmission at a population level by yearly repeated screening, treatment and partner notification to reduce the risk of exposure to chlamydia, and not to an individual effect of interruption of ascending infection. [37] [38] [39] Implications for chlamydia screening programmes Distinguishing between register-based and opportunistic approaches is important for operational reasons because the way in which a screening programme is delivered in practice should reproduce the benefit to the target population observed in clinical trials. 5 In the United States, the Preventive Services Task Force requires direct evidence that the entire screening service achieves the primary health outcome. 40 In the United Kingdom 5, 41 and New Zealand, 42 national screening committees require evidence of effectiveness from high-quality randomized trials of the screening programme that is to be delivered. In most countries that recommend chlamydia screening of specified groups of asymptomatic individuals, tests are offered opportunistically, usually in health care settings. Our review shows that published trials about opportunistic chlamydia screening provide indirect short-term evidence of inadequate quality. Even where opportunistic screening services are coordinated nationally with defined service standards, coverage of regular screening and outcomes of opportunistic screening are difficult to measure because health service data on screening uptake are not routinely linked to data on chlamydia-associated complications and neither data source is linked to population records. Current data from the best-performing region in the National Chlamydia Screening Programme in England show that, in contrast to predicted uptake of 50%, 43 only 2.5% of 16-to 24-year-olds were screened in the past year, 44 and chlamydia positivity rates remain at 10-11%. 1 There are no performance indicators for the primary outcomes. 45 The Chlamydia Screening Implementation project in the Netherlands will show whether or not the uptake of a register-based approach with repeated yearly screening invitations 6 can achieve the results observed by Scholes et al. 23 and Østergaard et al.
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Implications for the evaluation of chlamydia screening Uptake of screening is not an adequate surrogate endpoint for trials of chlamydia screening because the level of coverage predicting a defined reduction in morbidity or transmission is not known. 46 Objective endpoints, such as ectopic pregnancy or tubal infertility, often require invasive diagnosis and are too rare or delayed to be used realistically in trials. Pelvic inflammatory disease is the most commonly used biological outcome because it is the most frequent acute complication of lower genital tract chlamydia and is strongly associated with impaired fertility. 34 Clinical diagnosis is, however, known to be insensitive, non-specific and subjective. 34, 47 If misclassification applies similarly to both screened and unscreened groups, the effect size would be attenuated. The diagnosis of lower abdominal symptoms could, however, be different in screened and unscreened women if the investigator is influenced by the chlamydia screening status. Since practitioners usually cannot be blinded to the screening allocation in trials, symptoms reported in follow-up consultations should be recorded in a standard way, with the final outcome assessment made by an independent blinded committee.
A reduction in chlamydia transmission, attributable to screening, would provide good primary evidence of effectiveness. Comparing chlamydia test positivity after a single screening round biases the result in favour of the screened group, which includes incident infections, while infections in the control group include prevalent infections that might have been present before the trial started. Ideally, the effect of chlamydia screening on chlamydia transmission would be determined in a population in whom prevalent infections had been detected and treated, for example following a prevalence study with high participation, follow-up, treatment and partner notification rates. The chlamydia screening intervention would then be implemented in randomly assigned areas over two or more screening intervals. The final comparison would be made between screened and unscreened communities in a followup prevalence survey.
This systematic review provides information about the limitations of published evidence about the effectiveness of chlamydia screening, which can be used to inform future research and decisions about the introduction of chlamydia screening programmes. Where chlamydia screening interventions have already been introduced, our findings can be used to help design studies to determine the most effective way to deliver and monitor the outcomes of chlamydia screening. Interventions that combine the advantages of both register-based and opportunistic screening approaches could reach a higher proportion of the target population than either method alone. 48 For example, regular postal invitations could be supplemented with opportunistic offers to eligible individuals who have not responded. Alternatively, an initial opportunistic offer of testing could be followed up by postal invitations to nonattenders. The effectiveness and cost-effectiveness of chlamydia screening require further evaluation in randomized trials over multiple screening rounds with primary biological endpoints to show that the programme does more good than harm at reasonable cost.
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KEY MESSAGES
Chlamydia screening is widely believed to be an effective and cost-effective intervention to improve reproductive and sexual health.
The results of randomized controlled trials have overestimated the benefits of chlamydia screening on preventing pelvic inflammatory disease.
The chlamydia screening interventions that have been evaluated in randomized controlled trials are not those that are implemented in practice.
Clinical equipoise about the balance of benefits and harms of chlamydia screening programmes remains.
EFFECTIVENESS OF CHLAMYDIA SCREENING
